BBA
KYNB

Baker Bros. Advisors’s Kyntra Bio KYNB Stock Holding History

Baker Bros. Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,523
Closed -$643K – 104
2023
Q2 		$643K Sell
9,523
-95,972
-91% -$39.7M ﹤0.01% 101
2023
Q1 		$49.2M Buy
105,495
+50,487
+92% +$26.7M 0.27% 22
2022
Q4 		$22M Buy
55,008
+22,379
+69% +$8.57M 0.13% 39
2022
Q3 		$10.6M Hold
32,629
– – 0.07% 61
2022
Q2 		$8.61M Buy
32,629
+9,359
+40% +$2.39M 0.05% 67
2022
Q1 		$6.99M Buy
23,270
+64
+0.3% +$22.3K 0.04% 77
2021
Q4 		$8.18M Buy
+23,206
New +$7.23M 0.04% 82

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baker Bros. Advisors's KYNB Position: Q3 2023 in Review

Baker Bros. Advisors sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 9,523 shares — an estimated $643K sold.

Baker Bros. Advisors first reported a position in KYNB in Q4 2021 and held it in 7 quarters. The position peaked at $49.2M in Q1 2023. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

  • Baker Bros. Advisors reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
  • Baker Bros. Advisors sold 9,523 Kyntra Bio shares in Q3 2023, an estimated $643K.
  • Baker Bros. Advisors first reported a position in Kyntra Bio in Q4 2021 and held it in 7 quarters.
  • Baker Bros. Advisors's Kyntra Bio position peaked at $49.2M in Q1 2023.
  • 110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.